Nov 15, 2011 08:00 EST ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB. The acquisition further expands ViroPharma’s orphan disease commercial product pipeline. ViroPharma has paid an upfront closing cost of 220 million Swedish kroner (SEK) or $33.6 million in US dollars (USD). Additionally, there are contingent milestone payments of up to 860 million SEK.
Tag: hydrocortisone
Press Releases
Nov 07, 2011 07:00 EST The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren® (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
Jul 22, 2011 09:20 EDT The Swedish specialty pharma company, DuoCort Pharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorisation of its product Plenadren, a novel treatment for adrenal insufficiency.
Videos
Apr 14, 2010 05:38 EDT
DuoCort has developed an improved treatment for patients with adrenal insufficiency, a rare disease for which DuoCort has orphan drug designations in Europe and the USA. The new treatment is a dual release. This means it has an outer layer that immediately releases the drug and an inner core that releases the drug over the day to mimic the body´s own release of cortisol.
Length 2:48
